- Receiving testosterone therapy plus opioids was associated with significantly lower rates of all-cause mortality and lower incidence of major adverse cardiovascular events (MACE), femoral or hip fractures, and anemia during a 6-year period vs receiving opioids alone in men with long-term opioid use and testosterone deficiency.
Why this matters
- Prescription opioid use is associated with testosterone deficiency, but there are few data on the outcomes of testosterone treatment in long-term opioid users.
- A nationwide cohort study on male long-term opioid users with testosterone deficiency (n=21,272).
- Funding: Department of Veterans Affairs; others.
- 14,121 individuals received testosterone; 7151 individuals did not.
- Opioid users who received testosterone vs those without testosterone were more likely to have:
- obesity (49.0% vs 43.7%; P<.001 and>
- hyperlipidemia (48.8% vs 43.0%; P<.001>
- coronary artery disease (12.9% vs 15.9%; P<.001 and>
- stroke (1.3% vs 2.4%; P<.001>
- all-cause mortality (aHR, 0.51; 95% CI, 0.42-0.61),
- MACE (aHR, 0.58; 95% CI, 0.51-0.67),
- femoral/hip fractures (aHR, 0.68; 95% CI, 0.48-0.96), and
- anemia (aHR, 0.73; 95% CI, 0.68-0.79).
- Observational design.
Coauthored with Chitra Ravi, MPharm